My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    Pracinostat (SB939)
    Pracinostat (SB939)

    Price:
    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V0276
    CAS #: 929016-96-6Purity ≥98%

    Description: Pracinostat (formerly SB-939) is a novel, potent and orally bioavailable pan-HDAC (histone deacetylase) inhibitor with potential anticancer activity. It exhibits relatively higher selectivity (more than 1000-fold) for class I, class II and class IV HDACs rather than class III HDACs. It shows potent anti-proliferative activity in vitro against a wide range of cancer cell lines, including colon cancer, ovarian cancer, prostate carcinomas, acute myeloid leukaemia (AML) and B cell lymphoma. As of March 2014, pracinostat has been granted by FDA Orphan Drug status for the treatment of acute myelocytic leukemia (AML) and T-cell lymphoma.

    References: Mol Cancer Ther. 2010 Mar;9(3):642-52; Br J Cancer. 2011 Mar 1;104(5):756-62.

    Related CAS: 929016-97-7 (TFA), 929016-96-6 (free base), 929016-98-8 (2HCl)

    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Related Products
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review


    Molecular Weight (MW)358.48
    FormulaC20H30N4O2
    CAS No.929016-96-6
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Solubility (In vitro)DMSO: 72 mg/mL (200.8 mM)
    Water: <1 mg/mL
    Ethanol: 27 mg/mL (75.3 mM)
    Solubility (In vivo)1% DMSO+30% polyethylene glycol+1% Tween 80: 30 mg/mL
    SynonymsSB939; SB-939; SB 939

    Chemical Name: (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide

    InChi Key: JHDKZFFAIZKUCU-ZRDIBKRKSA-N

    InChi Code: InChI=1S/C20H30N4O2/c1-4-7-8-19-21-17-15-16(10-12-20(25)22-26)9-11-18(17)24(19)14-13-23(5-2)6-3/h9-12,15,26H,4-8,13-14H2,1-3H3,(H,22,25)/b12-10+

    SMILES Code: O=C(NO)/C=C/C1=CC=C2N(CCN(CC)CC)C(CCCC)=NC2=C1




    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      •  
      • V1
      •  
      • C2
      •  
      • V2
    In Vitro

    In vitro activity: SB939 has a 100-fold greater selectivity for HDACs than for Zn-binding non-HDAC enzymes, receptors, and ion channels. SB939 is a potent inhibitor of HDAC class I isoenzymes, HDAC1, HDAC2, HDAC3 and HDAC8 with the IC50 values ranging from 43 nM to 140 nM. SB939 inhibits HDAC class II isoenzymes , HDAC4, HDAC5, HDAC7, HDAC9 and HDAC10 significantly with the IC50 values ranging from 40 nM to 137 nM, with the exception of HDAC6 which shows IC50 of 1008 nM. It markedly inhibits HDAC11 of the HDAC class IV enzymes with IC50 of 93 nM, but shows no inhibitory activity against SIRT 1 of the class III HDACs. SB939 shows significant antiproliferative activity against a wide variety of tumor cell lines, especially Leukemia cells and cutaneous T-cell Lymphoma cells with IC50 values ranging from 50 nM (H9 cells) to 170 nM (HEL92.1.7 cells).


    Kinase Assay: All recombinant HDAC enzymes, with the exception of SIRT1, are cloned and expressed in S*BIO. The reaction mix containing 2.5 or 5 μL of the HDAC isoenzyme, assay buffer (25 mM Tris-HCl, pH 7.5; 137 mM NaCl; 2.7 mM KCl, 1 mM MgCl2 and 1 mg/mL BSA), different concentrations of SB939, and the fluorogenic deacetylase substrate Flour de LysTM in a total reaction volume of 33 μL is incubated at room temperature for 2 hours. 16 μL of Flour de LysTM developer is added and incubated for an additional 10 minutes. The emitted light is measured at 460 nm in a microplate reader. IC50 values are generated using the XLfit software.


    Cell Assay: Cells (HCT116, A2780, ACHN, MCF7, HL-60) are seeded in 96-well plates in the log growth phase at a predetermined optimal density, and rested for 24 hours (adherent cells) or 2 hours (suspension cells), respectively. They are exposed to different concentrations of SB939 for 96 hours. Cell proliferation assays are done using either the CyQUANT cell proliferation assay kit for adherent cells or the CellTiter96 Aqueous One solution cell proliferation kit for suspension cells.

    In VivoAdministration of SB939 (25 mg/kg to 100 mg/kg) displays a dose-dependent antitumor efficacy in a xenograft mice model of human colorectal cancer (HCT-116). This is approximately twice as efficacious as SAHA: SB939 causing a tumor growth inhibition of 94% versus 48% by SAHA with both at the maximum tolerated dose. Oral administration of SB939 at a dose of 50 mg/kg or 75 mg/kg in the APCmin genetic mice model of early-stage colon cancer markedly reduces the number of tumors , decreases cumulative hemocult scores and increases hematocrit values more effectively than 5-fluorouracil.
    Animal modelBALB/c nude mice bearing HCT-116 human colon cancer xenografts, Male and APCmin mice
    Formulation & DosageDissolved in DMSO and prepared in 0.5% methylcellulose (w/v) and 0.1% Tween-80 in water; 25, 50, 75, or 100 mg/kg; Oral administration
    References

    Mol Cancer Ther. 2010 Mar;9(3):642-52; Br J Cancer. 2011 Mar 1;104(5):756-62.


    These protocols are for reference only. InvivoChem does not independently validate these methods.

     

    Pracinostat (SB939)

    Pracinostat (SB939)

     

    Pracinostat (SB939)


    In vivo efficacy studies in HCT-116 xenografts to optimize the dosing schedule. Mol Cancer Ther.2010 Mar;9(3):642-52. 
     

    Pracinostat (SB939)

    Antitumor activity of SB939 in the Apcmin genetic colon cancer mouse model. Mol Cancer Ther. 2010 Mar;9(3):642-52. 


    评论

      Home Prev Next Last page / pices

      发评论

      ×
      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      prompt
      Do you confirm the receipt?